Yumanity’s corporate restructuring means the biotech is now exploring “strategic alternatives” that could include a sale of the company or its assets. The biotech’s lead drug candidate is an experimental Parkinson’s disease drug currently in Phase 1 testing.
Cambridge startup Yumanity Therapeutics just closed out an impressive $45 million Series A – meant to fuel its yeast-based drug discovery platform through preclinical development. The investor syndicate is an interesting blend of strategics and institutional firms. The round was led by Fidelity, with participation from Redmile Group, Alexandria Venture Investments, Biogen, Sanofi-Genzyme BioVentures and […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Looks like Obama has appointed quite the A-team to help the Precision Medicine Initiative shapeshift into something with some actual… shape. The $215 million initiative was first discussed at a two-day workshop mid-February that helped flesh out the plan’s aims. This is step two. Outside of the expected team of academicians and policy experts, there’s a smattering of private sector […]